FREEPORT, N.Y., Feb. 5 /PRNewswire/ -- AGI Dermatics today announced new comparative clinical data that indicates a novel compound of 4% hydroquinone and L-ergothioneine (HQ/EGT) reduces melanin significantly faster (twice as much) and with less irritation than traditional HQ formulation with steroids and a retinoid. The research was presented in the Poster Session at the 65th Annual Meeting of the American Academy of Dermatology in Washington, D.C.
"Our clinical study examined the depigmenting properties of a new cream containing 4% HQ and a patented super antioxidant, EGT," said Dan Yarosh, PhD, President, AGI Dermatics. "We found that the HQ/EGT combination is extremely effective in eradicating dyschromia and worked significantly faster than standard HQ formulas, with far less irritation. This is good news for physicians who prescribe HQ as it may increase patient compliance and treatment satisfaction."
The study compared the findings of test patches of Melanoderm-B tissues from MatTek treated daily with 2ul/cm(2) of an HQ/EGT compound cream and patches treated with an equal amount of a cream containing 4% HQ, 0.01% fluocinolone acetonide, (a steroid) and 0.05% tretinoin, a retin-a (HA/F+T). After seven days of treatment, both HQ/EGT and HQ/F+T treated tissues lacked melanin, while the melanocytes in the untreated tissues exhibited a high level of melanin and dendritic (immune) cells. The HQ/EGT treated tissue showed the inhibitory effect on melanin two times faster than the tissue treated with HQ/F+T.
The study also assessed the rate of irritation and its effect on the skin comparing the HQ/EGT formula with three other HQ products including an HQ/F+T lotion. Treatments were administered to 34 subjects five days per week for three weeks. The data showed the semi-occluded patches treated with the HQ/EGT lotion were found to be significantly less irritating by 2.6 times less than patches treated with HQ/F+T. All treatment areas were scored on a scale of zero (no irritation) to four (severe irritation); once a treatment area received a score of three or greater, treatment of that area was terminated. Termination of treatment with the HQ/EGT lotion was a significant 30% less than treatment with HQ/F+T.
AGI Dermatics is the developer of Remergent, a doctor-dispensed skincare line based on the science of DNA repair. AGI recently introduced Remergent HQ, a prescription formula that includes HQ with EGT, a patented, proprietary super antioxidant.
AGI Dermatics is the bio-pharmaceutical laboratory that has led the research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell-signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. http://www.agiderm.com
For press inquiries please contact RPR Marketing Communications at 212-317-1462.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Daniel Yarosh, PhD, President, AGI Dermatics http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=57840
AGI DermaticsCONTACT: RPR Marketing Communications, +1-212-317-1462, for AGI Dermatics
Web site: http://www.agiderm.com//
